Literature DB >> 1715237

Interleukin-6 does not support interleukin-2 induced generation of human lymphokine-activated killer cells.

H G Klingemann1, E Wong.   

Abstract

The activity of lymphokine-activated killer (LAK) cells is supported by various cytokines. The objective of this study was to see if recombinant interleukin-6 (IL-6) either alone or in combination with interleukin-2 (IL-2) has any effect on the generation of LAK cells. Peripheral blood mononuclear cells of healthy donors were cultured for 4 or 6 days with both cytokines either alone or in combination. LAK activity against K562 and natural killer-resistant Daudi cells was assessed by a 4-h and an 18-h 51Cr-release assay at various effector to target ratios. IL-6 alone in increasing concentrations did not induce LAK cell activity. Neither additive nor synergistic effects of IL-6 with IL-2 were observed. Immunofluorescence analysis with phycoerythrin-conjugated anti-CD56 antibody demonstrated that IL-6 could not maintain or increase the number of CD56-positive cells over a 6-day culture period. These results suggest that IL-6 does not support LAK cell generation by itself or increase LAK cell activity in combination with IL-2.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1715237     DOI: 10.1007/bf01741600

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  14 in total

1.  Monocyte-dependent, serum-borne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients.

Authors:  K Itoh; N R Pellis; C M Balch
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  The effects of IL-4 on human natural killer cells. A potent regulator of IL-2 activation and proliferation.

Authors:  A Nagler; L L Lanier; J H Phillips
Journal:  J Immunol       Date:  1988-10-01       Impact factor: 5.422

3.  The use of 51Cr release as a measure of lymphocyte-mediated cytolysis in vitro.

Authors:  R D Stulting; G Berke
Journal:  Cell Immunol       Date:  1973-12       Impact factor: 4.868

4.  Interleukin-6 and interleukin-1 production in acute leukemia with monocytoid differentiation.

Authors:  C E van der Schoot; P Jansen; M Poorter; M R Wester; A E von dem Borne; L A Aarden; R H van Oers
Journal:  Blood       Date:  1989-11-01       Impact factor: 22.113

5.  Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.

Authors:  B Brooks; R C Rees
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

6.  Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.

Authors:  T M Ellis; R S McKenzie; P E Simms; B A Helfrich; R I Fisher
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

7.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Authors:  S A Rosenberg; M T Lotze; L M Muul; S Leitman; A E Chang; S E Ettinghausen; Y L Matory; J M Skibber; E Shiloni; J T Vetto
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

8.  Production of hybridoma growth factor by human monocytes.

Authors:  L A Aarden; E R De Groot; O L Schaap; P M Lansdorp
Journal:  Eur J Immunol       Date:  1987-10       Impact factor: 5.532

9.  Interleukin 5 enhances interleukin 2-mediated lymphokine-activated killer activity.

Authors:  T Aoki; H Kikuchi; S Miyatake; Y Oda; K Iwasaki; T Yamasaki; T Kinashi; T Honjo
Journal:  J Exp Med       Date:  1989-08-01       Impact factor: 14.307

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

View more
  1 in total

1.  Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity.

Authors:  C Scheid; R Young; R McDermott; L Fitzsimmons; J H Scarffe; P L Stern
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.